Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT"

Circulation. 2016 Mar 29;133(13):e463. doi: 10.1161/CIRCULATIONAHA.116.020947.
No abstract available

Publication types

  • Letter
  • Kommentar

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Anticholesteremic Agents / therapeutic use*
  • C-Reactive Protein / analysis*
  • Cholesterol, LDL / blood*
  • Ezetimibe / therapeutic use*
  • Female
  • Humans
  • Male
  • Simvastatin / therapeutic use*

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • C-Reactive Protein
  • Simvastatin
  • Ezetimibe